DNA

Ginkgo Bioworks' stock has been volatile in the past six months. In August 2026, the company reported Q2 2026 earnings with a smaller-than-expected loss per share but a 48% year-over-year revenue decline, causing a share price drop. Despite this, it secured government contracts in August 2026 to establish autonomous labs at institutions like MIT and Caltech. A key partnership with Eli Lilly's TuneLab in mid-September 2026, focusing on AI-driven drug discovery, significantly boosted investor confidence, leading to a nearly 120% one-month stock gain. In September 2026, Ginkgo also announced plans for an autonomous lab at Novo's new U.S. R&D site. Further, in October 2026, it partnered with the National Science Foundation (NSF) X-Labs for autonomous laboratory access and protein testing. As of October 7, 2026, the stock price was $11.47, reflecting a 24.13% decline over the past year from September 2025 to September 2026.